The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

作     者：Cui Jiujie Fu Qihan Chen Xiaobing Wang Yanling Li Qi Wang Feng Li Zhihua Dai Guanghai Wang Yusheng Zhang Hongmei Liang Houjie Zhou Jun Yang Liu Wang Fenghua Zheng Leizhen Chen Xiaofeng Gong Ping Liu Jiang Yuan Ying Wang Lin Cheng Yuejuan Zhang Jun Zhou Yuhong Guo Weijian Zhan Xianbao Zou Zhengyun Li Da Zeng Shan Li Enxiao Li Zhiwei Teng Zan Cao Dan Kan Jie Xiong Jianping Quan Ming Yao Jiayu Yang Haiyan Wang Liwei 

作者机构：Department of Medical Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China Department of Medical Oncology The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou China Department of Medical Oncology Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou China Department of Medical Oncology Shanghai General Hospital Shanghai Jiao Tong University Shanghai China Department of Medical Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China Department of Medical Oncology Sun Yat-sen Medical Hospital Sun Yat-sen University Guangzhou China Medical Oncology Chinese PLA General Hospital Beijing China Department of Gastrointestinal Oncology Shanxi Provincial Cancer Hospital Affiliated to Shanxi Medical University Taiyuan China Department of Clinical Oncology Xijing Hospital Air Force Medical University Xi’an China Department of Oncology and Southwest Cancer Center Southwest Hospital Third Military Medical University (Army Military Medical University) Chongqing China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing) Peking University Cancer Hospital & Institute Beijing China Cancer Center Department of Medical Oncology Zhejiang Provincial People’s Hospital People’s Hospital of Hangzhou Medical College Hangzhou China Department of Medical Oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China Oncology Department Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of Medicine Shanghai China Department of Oncology the First Affiliated Hospital with Nanjing Medical University Nanjing China Department of Oncology The First Affiliated Hospital School of Medicine Shihezi University Shihezi China Department of Oncology People’s Hospital of Xinjiang Uygur Autonomous Region Xinjiang China Department of Medical Oncology the Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang Province China Department of Medical Oncology Hainan Genderal Hospital Haikou China Division of Medical Oncology Peking Union Medical College Hospital Beijing China Department of Oncology Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China Department of Medical Oncology Shanghai Zhongshan Hospital Fudan University Shanghai China Department of Medical Oncology Fudan University Shanghai Cancer Center Shanghai China Department of Medical Oncology Changhai Hospital of Shanghai Navy Medical University Shanghai China Comprehensive Cancer Centre of Drum Tower Hospital Medical School of Nanjing University Clinical Cancer Institute of Nanjing University Nanjing China Department of Medical Oncology Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou China Department of Medical Oncology Xiangya Hospital Central South University Changsha China Department of Medical Oncology the First Affiliated Hospital of Xi’an Jiaotong University Xi’an China Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin China Department of Medical Oncology The First Hospital of China Medical University Shenyang China Department of Medical Oncology West China Hospital Sichuan University Chengdu China Department of Medical Oncology Qinghai Provincial People’s Hospital Xi’ning China Department of Oncology The First Affiliated Hospital of Nanchang University Nanchang China Department of Oncology Shanghai East Hospital School of Medicine Tongji University Shanghai China 

出 版 物：《胰腺病学杂志(英文)》 (Journal of Pancreatology)

年 卷 期：2024年第7卷第1期

页      面：1-9页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Innovative Research Team of High-level Local University in Shanghai, (SHSMU-ZDCX20210802) Innovative Research Team of High-level Local University in Shanghai National Natural Science Foundation of China, NSFC, (82272906, 81874048, 82171824) National Natural Science Foundation of China, NSFC Shanghai Municipal Health Commission, (2019CXJQ03) Shanghai Municipal Health Commission CSCO Clinical Oncology Research Foundation, (Y-2019AZZD-0513) Health and Family Planning Commission of Sichuan Province, (2018ZHYL0223) Health and Family Planning Commission of Sichuan Province Shanghai Municipal Education Commission, (20161312) Shanghai Municipal Education Commission Clinical Research Plan of SHDC, (SHDC2020CR1035B) National Key Research and Development Program of China, NKRDPC, (2019YFC1315900) National Key Research and Development Program of China, NKRDPC Scientific and Technological Innovation Project of Science and Technology Commission of Shanghai Municipality, (21JC1404300) 

主　　题：Advanced pancreatic cancer China Pancreas Data Center Chinese First-line regimens Real-world study 

摘      要：Objective: Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center ***: A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was ***: The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combined with oxaliplatin/cisplatin (GEMOX/GP) (7.6%). The AS and GS/X regimens were associated with the highest PFS ***: This is the first study to report multicenter, real-world data regarding advanced pancreatic cancer in China. Results revealed that real-world treatment options differed from guideline recommendations, and PFS was shorter than that in previously reported data. Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recomm